Osteoprotection in patients with non-metastatic hormone-sensitive prostate cancer (mHSPC) receiving androgen-deprivation therapy (ADT): Real-world data from Germany, presented by d-uo - Klier, J; König, F; Schönfelder, R (Akt Urol, 2022)
et al.